Key Takeaways
- Takeda is realigning its R&D priorities focusing on four core modalities, moving away from high-risk early-stage programs.
- The company highlights its strongest late-stage pipeline, featuring six programs that could lead to significant market opportunities.
- Takeda is adopting option-based deals and is determined to pursue transformative treatments in both rare and more common diseases.
Strategic Shift at Takeda
Amid ongoing economic challenges, Takeda Pharmaceuticals is adapting its research and development (R&D) strategy to enhance efficiency and better meet patient needs. During the J.P. Morgan Healthcare Conference, the company’s R&D chief, Andy Plump, M.D., Ph.D., emphasized the need to respond to evolving market conditions, particularly influenced by the Inflation Reduction Act (IRA). The selection of drugs for Medicare price negotiations underscores the importance of this strategic shift.
Following a substantial restructure last year, Takeda now boasts what it claims to be the “most robust late-stage pipeline” in its history, with six programs involving 14 studies set to advance soon. Among these are promising candidates for narcolepsy type 1, psoriasis, and chronic blood cancer polycythemia vera, all expected to yield significant data by year’s end.
Realizing this maturity in pipeline development necessitated raising standards, leading to the elimination of several mid-stage programs, including a CD19 CAR-NK cell therapy and a small molecule candidate known as subasumstat. Takeda has narrowed its focus from a broad range of 10-12 modalities to four—small molecules, biologics, antibody-drug conjugates, and allogeneic cell therapies—based on past successes and the potential to enhance internal capabilities.
Furthermore, this new approach is expected to shift the culture within Takeda, fostering a more strategic mindset among employees who previously operated on a premise of rapid expansion. The company will now prioritize select initiatives over a scattergun strategy, producing more refined analyses around potential partnerships. Plump articulated that the company will be more judicious in its partnerships and investments, having moved away from heavily funding early-stage, high-risk programs which often led to failures.
In unveiling this new investment strategy, Plump noted that early-stage programs will only be continued if they reach a critical inflection point swiftly. The company is also venturing into option-based deals, where financial efficiency is maximized by having partners manage program costs while Takeda retains the option to acquire successful candidates at a lower price.
An example of this approach is Takeda’s recent agreement with Keros Therapeutics, involving an upfront payment of $200 million plus up to $1.1 billion in milestone payments for the rights to its activin inhibitor, elritercept. This candidate, poised to undergo phase 3 testing as a treatment for anemia associated with blood cancers, could pose a competitive threat to existing treatments in the market.
While five out of the six of Takeda’s late-stage projects are intended for rare diseases, Plump clarified that the organization is not solely a rare disease-focused company. Historically associated with treatments for ultrarare conditions, Takeda seeks to broaden its perception by engaging in innovative therapies. The R&D leader contended that many of these ultrarare diseases present significant patient populations and pressing unmet medical needs, reinforcing their relevance within Takeda’s overarching investment strategy.
Currently, Takeda centers its efforts on three primary therapeutic areas: oncology, neuroscience, and what it terms GI-squared, targeting various gastrointestinal and inflammatory conditions. Through this strategic refocusing, Takeda aims to solidify and expand its role in delivering transformative medicines for both rare and more prevalent diseases.
The content above is a summary. For more details, see the source article.